Novo Nordisk A/S (NVO - Free Report) is scheduled to release its second-quarter 2022 results on Aug 4.
The company’s earnings surprise history has been excellent so far, with its earnings beating the Zacks Consensus Estimate in each of the trailing four quarters, the average being 7.56%. In the last reported quarter, Novo Nordisk delivered an earnings beat of 10.59%.
Shares of Novo Nordisk have rallied 3.6% this year so far compared with the industry’s increase of 3.8%.
Let’s see how things are shaping up for the quarter to be reported.
Factors at Play
Novo Nordisk operates under two segments — Diabetes and Obesity Care, and Biopharmaceuticals.
Novo Nordisk’s revenues increased 24% in Danish kroner and were up 18% at constant exchange rate in the last reported quarter, driven by higher sales of Diabetes and Obesity Care products, a trend that most likely continued in the second quarter as well.
The Diabetes and Obesity Care segment sales grew substantially year-over-year in the last reported quarter, a trend that is likely to have continued in the second quarter as well.
Obesity Care (Saxenda and Wegovy) sales were up significantly year over year in the last reported quarter, a trend that is likely to have continued in the to-be-reported quarter.
Sales in the Rare disease segment grew marginally year over year in the last reported quarter, a trend that most likely continued in the to-be-reported quarter as well.
Higher costs driven by clinical activity for late-stage studies are likely to have escalated research and development costs in the second quarter.
Sales and distribution costs also increased year over year in the last reported quarter. This increase was due to International Operations and North America Operations reflecting the launch of Rybelsus and promotional activities related to Ozempic. The trend has most likely prevailed in the to-be-reported quarter.
Persistent pricing pressure within Diabetes Care, especially in the United States, is likely to have hurt sales in the second quarter.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Novo Nordisk this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Novo Nordisk is -1.73% as the Zacks Consensus Estimate currently stands at 87 cents per share and the Most Accurate Estimate is currently pegged at 85 cents per share.
Zacks Rank: NVO currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
BioNTech SE (BNTX - Free Report) has an Earnings ESP of +10.88% and a Zacks Rank #2.
BioNTech’s stock has plunged 35.9% year to date. BioNTech topped earnings estimates in all the last four quarters. BNTX has a four-quarter earnings surprise of 56.87%, on average. BNTX is scheduled to release its second-quarter 2022 results on Aug 8.
Gilead Sciences, Inc. (GILD - Free Report) has an Earnings ESP of +0.17% and a Zacks Rank #3.
Gilead’s stock has declined 17.7% year to date. Gilead topped earnings estimates in three of the last four quarters. GILD has a four-quarter earnings surprise of 6.30%, on average. GILD is scheduled to release its second-quarter 2022 results on Aug 2.
Horizon Therapeutics plc has an Earnings ESP of +4.97% and a Zacks Rank #3.
Horizon’s stock has decreased 23% year to date. Horizon topped earnings estimates in all the last four quarters. HZNP has a four-quarter earnings surprise of 29.80%, on average. HZNP is scheduled to release its second-quarter 2022 results on Aug 3.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Novo Nordisk A/S (NVO - Free Report) is scheduled to release its second-quarter 2022 results on Aug 4.
The company’s earnings surprise history has been excellent so far, with its earnings beating the Zacks Consensus Estimate in each of the trailing four quarters, the average being 7.56%. In the last reported quarter, Novo Nordisk delivered an earnings beat of 10.59%.
Shares of Novo Nordisk have rallied 3.6% this year so far compared with the industry’s increase of 3.8%.
Let’s see how things are shaping up for the quarter to be reported.
Factors at Play
Novo Nordisk operates under two segments — Diabetes and Obesity Care, and Biopharmaceuticals.
Novo Nordisk’s revenues increased 24% in Danish kroner and were up 18% at constant exchange rate in the last reported quarter, driven by higher sales of Diabetes and Obesity Care products, a trend that most likely continued in the second quarter as well.
The Diabetes and Obesity Care segment sales grew substantially year-over-year in the last reported quarter, a trend that is likely to have continued in the second quarter as well.
Obesity Care (Saxenda and Wegovy) sales were up significantly year over year in the last reported quarter, a trend that is likely to have continued in the to-be-reported quarter.
Sales in the Rare disease segment grew marginally year over year in the last reported quarter, a trend that most likely continued in the to-be-reported quarter as well.
Higher costs driven by clinical activity for late-stage studies are likely to have escalated research and development costs in the second quarter.
Sales and distribution costs also increased year over year in the last reported quarter. This increase was due to International Operations and North America Operations reflecting the launch of Rybelsus and promotional activities related to Ozempic. The trend has most likely prevailed in the to-be-reported quarter.
Persistent pricing pressure within Diabetes Care, especially in the United States, is likely to have hurt sales in the second quarter.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Novo Nordisk this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Novo Nordisk is -1.73% as the Zacks Consensus Estimate currently stands at 87 cents per share and the Most Accurate Estimate is currently pegged at 85 cents per share.
Zacks Rank: NVO currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
BioNTech SE (BNTX - Free Report) has an Earnings ESP of +10.88% and a Zacks Rank #2.
BioNTech’s stock has plunged 35.9% year to date. BioNTech topped earnings estimates in all the last four quarters. BNTX has a four-quarter earnings surprise of 56.87%, on average. BNTX is scheduled to release its second-quarter 2022 results on Aug 8.
Gilead Sciences, Inc. (GILD - Free Report) has an Earnings ESP of +0.17% and a Zacks Rank #3.
Gilead’s stock has declined 17.7% year to date. Gilead topped earnings estimates in three of the last four quarters. GILD has a four-quarter earnings surprise of 6.30%, on average. GILD is scheduled to release its second-quarter 2022 results on Aug 2.
Horizon Therapeutics plc has an Earnings ESP of +4.97% and a Zacks Rank #3.
Horizon’s stock has decreased 23% year to date. Horizon topped earnings estimates in all the last four quarters. HZNP has a four-quarter earnings surprise of 29.80%, on average. HZNP is scheduled to release its second-quarter 2022 results on Aug 3.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Get the latest research report on NVO - FREE
Get the latest research report on GILD - FREE
Get the latest research report on BNTX - FREE